Therapeutic Effects of Topical Tranexamic Acid in Comparison with Hydroquinone in Treatment of Women with Melasma

Najmolsadat Atefi, Behzad Dalvand, Mahammadreza Ghassemi, Golnaz Mehran, Amir Heydarian, Najmolsadat Atefi, Behzad Dalvand, Mahammadreza Ghassemi, Golnaz Mehran, Amir Heydarian

Abstract

Introduction: Few studies have focused on therapeutic as well as side effects of tranexamic acid (TXA) as a topical drug compared to other topical drugs in treating melasma. The present study aimed to assess and compare the beneficial therapeutic effects and also side effects of local TXA in comparison with hydroquinone in treating women with melasma.

Methods: This randomized double-blinded clinical trial was performed on 60 women who suffered from melasma and were referred to the skin disorders clinic at the Rasoul-e-Akram hospital in Tehran in 2015. The patients were then randomly assigned via computerized randomization to two groups: group A received TXA%5 (topically twice a day for 12 weeks in the location of the melasma) and group B (received hydroquinone 2% with the same treatment order). Prior to intervention and at 12 weeks after intervention, the intensity and extension of melasma were assessed based on the Melasma Area and Severity Index (MASI) scoring method.

Results: The mean MASI score in both treatment groups decreased considerably after completion of treatment and was not significant between the two groups. No side effects were detected in group A, but 10% of those in group B complained of drug-related side effects including erythema and skin irritation (p = 0.131). Regarding the level of patient satisfaction, the patients in group A had a significantly higher level of satisfaction level of 33.3% compared with 6.7% in group B (p = 0.015) (Fig. 9). Multivariate linear regression modeling with the presence of age, history of systemic disorder, drug history, and family history of melasma demonstrated no difference in the mean MASI between the two groups.

Conclusion: Topical use of TXA significantly reduced both melanin level and MASI score. Given its high efficiency and low drug side effects, this regimen results in high patient satisfaction compared with topical hydroquinone. IRCT code: IRCT2016040627220N2.

Keywords: Hydroquinone; Melasma; Tranexamic acid; Women.

Figures

Fig. 1
Fig. 1
A. Pretreatment TAX
Fig. 2
Fig. 2
B. Pretreatment TAX
Fig. 3
Fig. 3
C. Pretreatment HYD
Fig. 4
Fig. 4
D. Preteatment HYD
Fig. 5
Fig. 5
A. Treatment TXA, after 12 weeks
Fig. 6
Fig. 6
B. Treatment TXA, after 12 weeks
Fig. 7
Fig. 7
C. Treatment HYD, after 12 weeks
Fig. 8
Fig. 8
D. Treatment HYD, after 12 weeks
Fig. 9
Fig. 9
The level of satisfaction of the two treatment regimens in melasma. HYD hydroquinone, TXA tranexamic acid
Fig. 10
Fig. 10
Pathogenesis of melasma and role of tranexemic acid (TXA), plasminogen activator (PA), vascular endothelial growth factor (VEGF)

References

    1. Miot LD, Miot HA, Silva MG, Marques ME. Physiopathology of melasma. An Bras Dermatol. 2009;84:623–635. doi: 10.1590/S0365-05962009000600008.
    1. Walker SL, Shah M, Hubbard VG, Pradhan HM, Ghimire M. Skin disease is common in rural Nepal: results of a point prevalence study. Br J Dermatol. 2008;158:334–338. doi: 10.1111/j.1365-2133.2007.08395.x.
    1. Alakloby OM. Pattern of skin diseases in Eastern Saudi Arabia. Saudi Med J. 2005;26:1607–1610.
    1. Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA., Jr Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(388):390.
    1. Perez M, Luke J, Rossi A. Melasma in Latin Americans. J Drugs Dermatol. 2011;10:517–523.
    1. Sheth VM, Pandya AG. Melasma: a comprehensive update: part I. J Am AcadDermatol. 2011;65:689–697. doi: 10.1016/j.jaad.2010.12.046.
    1. Tamega Ade A, Miot LD, Bonfietti C, Gige TC, Marques ME, Miot HA. Clinical patterns and epidemiological characteristics of facial melasma in Brazilian women. J Eur Acad Dermatol Venereol. 2013;27:151–156. doi: 10.1111/j.1468-3083.2011.04430.x.
    1. Katsambas A, Antoniou C. Melasma. Classification and treatment. J Eur Acad Dermatol Venereol. 1995;4:217–223. doi: 10.1111/j.1468-3083.1995.tb00341.x.
    1. Lakhdar H, Zouhair K, Khadir K, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of chloasma in pregnant women. J Eur Acad Dermatol Venereol. 2007;21:738–742. doi: 10.1111/j.1468-3083.2007.02185.x.
    1. Wu S, Shi H, Wu H, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36(4):964–970. doi: 10.1007/s00266-012-9899-9.
    1. Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012; 14(3):150–154.
    1. Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 2016;41(5):480–485. doi: 10.1111/ced.12835.
    1. Maeda K, Naganuma M. Topical trans-4-aminomethyl cyclohexanecarboxylic acid prevents ultraviolet radiation-induced pigmentation. J Photochem Photobiol B. 1998;47:136–141. doi: 10.1016/S1011-1344(98)00212-7.
    1. Poojary S, Minni K. Tranxemic acid in melasma. J Pigment Disord. 2015;2:288.
    1. Maeda K, Tomitab Y. Mechanism of the inhibitory effect of tranexamic acid on melanogenesis in cultured human melanocytes in the presence of keratinocyte-conditioned medium. J Health Sci. 2007;53:389–396. doi: 10.1248/jhs.53.389.
    1. Zhang X, Yang X, Yang H, Yang Y. Study of inhibitory effect of acidum tranexamicum on melanin synthesis. Chin J Dermatovenereol Integr Tradit West Med. 2003;2:227–229.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться